Latest News about NVO
Recent news which mentions NVO
Hims & Hers Health Stock Is Tumbling Thursday: Here's Why
October 03, 2024
From Benzinga
Tandem Diabetes Insulin Pump Demand to Surge Despite Popular Demand Of Weight Loss Drugs, Bullish Analyst Says
October 02, 2024
From Benzinga
Eli Lilly Commits $4.5B To New Facility, Banking On Mounjaro, Zepbound's Weight Loss Success Despite Short-Term Stock Challenges
October 02, 2024
From Benzinga
Eli Lilly Invests $4.5B In New Medicine Foundry for Advanced Drug Manufacturing To Push US Pharma Boundaries
October 02, 2024
From Benzinga
Eli Lilly Nears First Trillion Pharma Title, But Investors Caution Amid Sky-High Valuation
October 02, 2024
From Benzinga
US HHS Reveal Cost Savings For 54 Prescription Drugs Including Novartis' Cancer Drug, Ozempic Could be Next
October 01, 2024
From Benzinga
Roche Fast-Tracks Obesity Drug Development, Eyes Over $3B Sales Potential
September 30, 2024
From Benzinga
'Stop Ripping Us Off' – Incredibly, Elon Musk And Bernie Sanders Seem To Agree On This One Thing – 'I Really Am With Bernie On This One'
September 29, 2024
Tickers
NVO
From Benzinga
Success in This New Battleground Could Make Eli Lilly and Novo Nordisk Stock Absolutely Fly for Years
September 28, 2024
From Motley Fool
Benzinga Bulls And Bears: Apple, Tesla, Novo Nordisk, Bitcoin — And Shiba Inu's Major Stablecoin Tease
September 28, 2024
From Benzinga
Latest Inflation Data Cements Fed's Interest Rate Call, S&P 500 Hits All-Time High, Biden Adviser Backs China EV Ban At Detroit Economic Club: This Week In The Markets
September 27, 2024
From Benzinga
If You Invested $1000 In This Stock 5 Years Ago, You Would Have $4,700 Today
September 27, 2024
From Benzinga
Cassava Sciences, enVVeno Medical And Other Big Stocks Moving Lower In Friday's Pre-Market Session
September 27, 2024
From Benzinga
Novo Nordisk Just Committed More Than $1.1 Billion to Make the Next Ozempic, but Is the Stock a Buy?
September 27, 2024
Tickers
NVO
From Motley Fool
Novo Nordisk And Evotec Collaborate On Stem Cell-Based Therapy Development
September 26, 2024
From Benzinga
Forget Novo Nordisk, Buy This Magnificent Dividend Stock Instead
September 26, 2024
From Motley Fool
EXCLUSIVE: Vivani Medical Advances Its Obesity Treatment Implant With New Clinical Trial in Australia
September 26, 2024
From Benzinga
Novo Nordisk's $600 Million Gambit Could Be a Game Changer for the Stock. Here's Why.
September 26, 2024
From Motley Fool
Lose Weight With Novo Nordisk Drugs, Gain Money With Stock
September 25, 2024
Tickers
NVO
From Benzinga
Popular Ozempic May Have New Use As Semaglutide Drugs Linked To Reduced Overdose Risk In Diabetic Opioid Users
September 25, 2024
From Benzinga
Can Novo Nordisk's Weight Loss Drug Ozempic Help Stem The Devastating Addiction Crisis? New Research Says Yes
September 25, 2024
From Benzinga
Bristol Myers-2seventy Bio Halt Phase 3 Trial For Abecma In Newly Diagnosed Myeloma Patients, Speeds Path To Profitability
September 25, 2024
From Benzinga
EXCLUSIVE: Novo Nordisk Faces Political Heat Over Weight-Loss Drug Prices Ahead Of Elections, Yet 'The Real Issue Is With The Middlemen'
September 25, 2024
From Benzinga
Novo Nordisk To Consider Ways For Patients To Affordably Access Weight Loss Drugs Ozempic, Wegovy, Says CEO
September 24, 2024
Tickers
NVO
From Benzinga
Novo Nordisk's Options: A Look at What the Big Money is Thinking
September 24, 2024
Tickers
NVO
From Benzinga
'Miracle' Weight Loss Drug Ozempic To Enter US Price Negotiations Within A Year, Novo Nordisk CEO Says Ahead Of Senate Hearing
September 24, 2024
From Benzinga
2 Weight-Loss Stocks That Could Rocket Higher This Year
September 24, 2024
From Motley Fool
Nasdaq-Traded Cannabinoid Biotech Corbus Pharma Stock Plunges 60%, But Analysts Say 'Buy The Dip' Now
September 23, 2024
From Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.